Allopurinol as an effective inhibitor of the enzyme xanthine oxidase (XO) has been used for several decades for the treatment of patients with gout and hyperuricemia. Because the inhibition of XO limits the formation of radical oxygen species as well as uric acid (UA) production, allopurinol has been used experimentally for the treatment of conditions associated with ischemia and reperfusion (I/R) injury.
Although there have been many ischemic organs treated in the laboratory with allopurinol, the heart has been of particular interest. Therefore, we emphasize our attention to the administration of XO inhibitors such as allopurinol on cardiac I/R as well as cardiac failure. Experimental data also support allopurinol as a possible consideration for biochemical support after acute myocardial infarction.
Anker and associates (Circulation. 2003;107:1991-1997) have observed a direct correlation between uric acid levels and mortality in treated heart failure patients. Anker and associates showed a 100% mortality rate in patients with UA levels 800 μmol/L or less over a period of 3 years. Comparing this to a 27% mortality rate in patients with UA levels 400 μmol/L or less over a period of 10 years, it seems that the suppression of XO activity ameliorates myocardial inefficiency, and poor vascular flow may present innovative contributions to the future treatment of I/R heart failure patients. Our review focuses on the role of allopurinol on ischemic hearts as well as those with added chronic heart failure.
De JongJW, SchoemakerRG, De JongeR. Enhanced expression and activity of xanthine oxidoreductase in the failing heart. J Mol Cell Cardiol. 2000; 32:2083–2089.
2.
GrangerDN, HollwarthME, ParksDA. Ischemia reperfusion injury: role of oxygen derived free radicals. Acta Physiol Scand. 1986; 548:47–63.
3.
McCordJM, FridovichI. The reduction of cytochrome c by milk xanthine oxidase. J Biol Chem. 1968; 243:5753–5760.
4.
OlsenJS, BallouDP, PalmerG, . The mechanism of action of xanthine oxidase. J Biol Chem. 1974; 249:4363–4382.
5.
NakamuraS, YamazakiI. One-electron transfer reactions in biochemical systems IV. A mixed mechanism in the reaction of milk xanthine oxidase with electron acceptors. Biochem Biophys Acta. 1969; 189:29–37.
6.
PacherP, NivorozhkinA, SzaboC. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006; 58:87–114.
7.
ElionG. The purine path to chemotherapy. Wellcome Research Laboratories, Burroughs Wellcome Co. Nobel lecture; December 8, 1988; Research Triangle Park, NC.
8.
MathruM, DriesDJ, BarnesL, . Tourniquet-induced exsanguination in patients requiring lower limb surgery. An ischemia-reperfusion model of oxidant and antioxidant metabolism. Anesthesiology. 1996; 84:14–22.
9.
AbadehS, CasePC, HarrisonR. Demonstration of xanthine oxidase in human heart. Biochem Soc Trans. 1992; 20:346S.
10.
EddyLJ, StewartJR, JonesHP, . Free radical producing enzyme, xanthine oxidase, is undetectable in human hearts. Am J Physiol. 1987; 253:H709–H711.
11.
GrumCM, GallaguarKP, KirshMM, . Absence of detectable xanthine oxidase in human myocardium. J Mol Cell Cardiol. 1989; 21:263–267.
12.
LiGR, FerrierGR. Effects of allopurinol on reperfusion arrhythmias in isolated ventricles. Am J Physiol Heart Circ Physiol. 1992; 263:341–348.
13.
MoensAL, ClaeysMJ, TimmermansJP, . Myocardial ischemia/reperfusion-injury; a clinical view on a complex pathophysiological process. Int J Cardiol. 2005; 100:179–190.
UkaiT, ChengCP, TachibanaH, . Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing induced heart failure. Circulation. 2001; 103:750–755.
18.
BorasoA, CeconiC, CargnoniA, . Oxidative stress and ventricular dysfunction in ischemic heart disease. Heart Fail Rev. 1999; 4:147–156.
19.
KielsteinJT, WoywodtA, SalpeterSR.Letter by Kielson, . regarding article, High-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acid. Circulation. 2007; 115:450–451.
20.
DeWallRA, VaskoKA, StanleyEL, . Responses of the ischemic myocardium to allopurinol. Am Heart J. 1971; 82:362–370.
21.
IsselE, LunA, PohleR, . Hypoxanthine levels in amniotic fluid: an indicator of fetal hypoxia?J Perinat Med. 1982; 10:221–225.
22.
KuboSH, RectorTS. Endothelium-dependent vasodilatation is attenuated in patients with heart failure. Circulation. 1991; 84:1589–1596.
23.
EllisSG, WynneJ, BraunwaldE, . Response of reperfusion-salvaged, stunned myocardium to inotropic stimulation. Am Heart J. 1984; 107:13–19.
24.
Grupo Italiano per lo Studio della Strepto Chinasi nell'Infarto Miocardio (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986; 327:397–401.
25.
ManningAS, ColtartDJ, HearseDJ. Ischemia and reperfusion-induced arrhythmias in the rat. Effects of xanthine oxidase inhibition with allopurinol. Circ Res. 1984; 55:545–548.
26.
ParksDA, BulkleyGB, GrangerDN. Role of oxygen-derived free radicals in digestive tract diseases. Surgery. 1983; 93:415–422.
27.
ReubenGM, VanhouttePM. Superoxide anion and hypoxia inactive endothelium-derived relaxing factor. Am J Physiol. 1986; 250:H822–H827.
28.
StullLB, LeppoMK, SzwedaL, . Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res. 2004; 95:1005–1011.
29.
TaggartDP, YoungV, KempM, . Lack of cardioprotective efficacy of allopurinol in coronary artery surgery. Heart. 1994; 71:177–181.
30.
KittlesonMM, HareJM. Xanthine oxidase inhibitors: an emerging class of drugs for heart failure. Eur Heart J. 2005; 26:1458–1460.
31.
WattsRWE, WatkinsPJ, MatthiasJQ, . Allopurinol and acute uric acid nephropathy. Br Med J. 1966; 1:205–208.
32.
YamanakaH, NishiokaK, SuzukiT, . Allopurinol metabolism in a patient with xanthine oxidase deficiency. Ann Rheum Dis. 1983; 42:684–686.
33.
LazarusHM, OwensML, HopfenbeckA. Allopurinol protection of hepatic nuclear function during hemorrhagic shock. Surg Forum. 1974; 25:10–12.
34.
LandmesserU, SpiekermannS, DikalovS, . Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine oxidase and extracellular superoxide dismutase. Circulation. 2002; 106:3073–3078.
35.
LeeWY, LeeSM. Synergistic protective effect of ischemic preconditioning and allopurinol on ischemia-reperfusion injury in rat liver. Biochem Biophys Res Commun. 2006; 349:1087–1093.
36.
AnkerSD, DoehnerD, RauchhausM, . Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003; 107:1991–1997.
37.
StrasakA, RuttmassE, BrantL, . Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem. 2008; 54:273–284.
38.
ElsayedNM, NakashimaJM, PostlethwaitEM. Measurement of uric acid as a marker of oxygen tension in the lung. Arch Biochem Biophys. 1993; 302:228–232.
39.
HartL, McGartollM, ChapmanH, . The composition of milk xanthine oxidase. J Biol Chem. 1970; 116:851–864.
40.
HashimotoY, ItohH, NishidaK. Rapid superoxide production by endothelial cells and their injury upon reperfusion. J Surg Res. 1994; 57:693–697.
41.
IansekR, PackhamD, AspeyBS, . An assessment of the possible protective effects of allopurinol in acute stroke. J Neurol Neurosurg Psychiatry. 1986; 49:585–587.
42.
McCordJM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985; 312:159–163.
43.
PeronatG. Purine metabolism and hyperuricemia states. The point of view of the rheumatologist. Contrib Nephrol. 2005; 147:1–21.
44.
WhalenDA, HamiltonDG, GanoteCE, . Effect of a transient period of ischemia on myocardial cells. Am J Pathol. 1974; 74:381–397.
45.
HuizerT, De JongJW, NelsonJA. Urate production by the human heart. J Cell Mol Cardiol. 1989; 21:691–695.
46.
LeyvaF, AnkerS, SwanJW, . Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997; 18:858–865.
47.
MasseyV, KomaiH, PalmerG, . On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d] pyrimidines. J Biol Chem. 1970; 245:2837–2844.
48.
JonesCE, CrowellJW, SmithEE. Significance of increased blood uric acid following extensive hemorrhage. Am J Physiol. 1968; 214:1374–1377.
49.
WoolliscroftJO, ColferH, FoxIH. Hyperuricemia in acute illness: a poor prognostic sign. Am J Med. 1982; 72:58–62.
50.
HambrechtR, FiehnE, WeiglC, . Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation. 1998; 98:2709–2715.
51.
PetersonDA, AsingerRW, ElspergerKL, . Reactive oxygen species may cause myocardial reperfusion injury. Biochem Biophys Res Commun. 1985; 127:87–93.
52.
OlsenJS, BallouDP, PalmerG, . The reaction of xanthine oxidase with molecular oxygen. J Biol Chem. 1974; 249:4350–4362.
53.
RundlesR, WyngaardenJT, HitchingsGH, . Trans Assoc Am Physicians. 1963; 76:126.
54.
DoehnerW, AnkerSD. Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure?Heart. 2005; 91:707–709.
55.
PatelB, KlonerRA. Analysis of reported randomized trials of streptokinase therapy for acute myocardial infarction in the 1980's. Am J Cardiol. 1987; 59:501–504.
56.
TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: phase I findings. N Engl J Med. 1985; 312:932–936.
57.
HitchingsGHJr. Selective inhibitors of dihydrofolate reductase. Wellcome Research Laboratories, Burroughs Wellcome Co. Nobel lecture; December 8, 1988; Research Triangle Park, NC.
58.
McGaurnSP, DavisLE, KrawczeniukMM. The pharmacokinetics of injectable allopurinol in newborns with hypoplastic left heart syndrome. Pediatrics. 1994; 94:820–823.
59.
FriedlHP, TillGO, RyanUS. Mediator-induced activation of xanthine oxidase in endothelial cells. J Fed Am Soc Exp Biol. 1989; 3:2512–2518.
60.
BermanRS, MartinW. Arterial endothelial barrier dysfunction: actions of the homocysteine and hypoxanthine-xanthine oxidase free radical generating system. Br Med J. 1993; 108:920–926.
61.
DoehnerW, SchoeneN, RauchhausM, . Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002; 105:2919–2624.
62.
EkelundUE, HarrisonRW, ShokekO. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res. 1999; 85:437–445.
63.
CappolaTP, KassDA, NelsonGS. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001; 104:2407–2411.
64.
AdachiH, MotomatsuK, YaraI. Effect of allopurinol (Zyloric) on patients undergoing open heart surgery. Jpn Circ J. 1979; 43:395–401.
65.
EngberdingN, SpiekermannS, SchaeferA, . Allopurinol attenuates left ventricular remolding and dysfunction after experimental myocardial infarction: a new action for an old drug?Circulation. 2004; 110:2175–2179.
66.
KoglerH, FraserH, McCuneS, . Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium. Cardiovasc Res. 2003; 59:882–592.
MellinV, IsabelleM, OudotA, . Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J. 2005; 26:1544–1550.
69.
LeyvaF, AnkerSD, GodslandIF, . Uric acid in chronic heart failure. Eur Heart J. 1998; 19:1814–1822.
70.
SaavedraWF, PaolocciN, JohnMESt., . Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res. 2002; 90:297–304.
71.
StruthersAD, DonnanPT, LindsayP, . Effect of allopurinol on mortality and hospitalizations in chronic heart failure: a retrospective cohort study. Heart. 2002; 87:229–234.
72.
BaldusS, KosterR, ChumleyP, . Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free Radic Biol Med. 2005; 39:1184–1190.
73.
AngdinM, SettergrenG, StarkopfJ, . Protective effect of antioxidants on pulmonary endothelial function after cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2003; 17:314–320.
74.
LindsayWG, Toledo-PereyraLH, FokerJE. Metabolic myocardial protection with allopurinol during cardiopulmonary bypass and aortic cross-clamping. Surg Forum. 1975; 26:259.
75.
BerryCE, HareJM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol. 2004; 555:589–606.
76.
LandmesserU, DrexlerH. Allopurinol and endothelial function in heart failure: future or fantasy?Circulation. 2002; 106:173–175.
